+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

In-silico comparison of two induction regimens (7 + 3 vs 7 + 3 plus additional bone marrow evaluation) in acute myeloid leukemia treatment



In-silico comparison of two induction regimens (7 + 3 vs 7 + 3 plus additional bone marrow evaluation) in acute myeloid leukemia treatment



Bmc Systems Biology 13(1): 18



Clinical integration of systems biology approaches is gaining in importance in the course of digital revolution in modern medicine. We present our results of the analysis of an extended mathematical model describing abnormal human hematopoiesis. The model is able to describe the course of an acute myeloid leukemia including its treatment. In first-line treatment of acute myeloid leukemia, the induction chemotherapy aims for a rapid leukemic cell reduction. We consider combinations of cytarabine and anthracycline-like chemotherapy. Both substances are widely used as standard treatment to achieve first remission. In particular, we compare two scenarios: a single-induction course with 7 days cytarabine and 3 day of anthracycline-like treatment (7 + 3) with a 7 + 3 course and a bone marrow evaluation that leads, in case of insufficient leukemic cell reduction, to the provision of a second chemotherapy course. Three scenarios, based on the leukemias growth kinetics (slow, intermediate, fast), were analyzed. We simulated different intensity combinations for both therapy schemata (7 + 3 and 7 + 3 + evaluation). Our model shows that within the 7 + 3 regimen a wider range of intensity combinations result in a complete remission (CR), compared to 7 + 3 + evaluation (fast: 64.3% vs 46.4%; intermediate: 63.7% vs 46.7%; slow: 0% vs 0%). Additionally, the number of simulations resulting in a prolonged CR was higher within the standard regimen (fast: 59.8% vs 40.1%; intermediate: 48.6% vs 31.0%; slow: 0% vs 0%). On the contrary, the 7 + 3 + evaluation regimen allows CR and prolonged CR by lower chemotherapy intensities compared to 7 + 3. Leukemic pace has a strong impact on treatment response and especially on specific effective doses. As a result, faster leukemias are characterized by superior treatment outcomes and can be treated effectively with lower treatment intensities. We could show that 7 + 3 treatment has considerable more chemotherapy combinations leading to a first CR. However, the 7 + 3 + evaluation regimen leads to CR for lower therapy intensity and presumably less side effects. An additional evaluation can be considered beneficial to control therapy success, especially in low dose settings. The treatment success is dependent on leukemia growth dynamics. The determination of leukemic pace should be a relevant part of a personalized medicine.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 066446575

Download citation: RISBibTeXText

PMID: 30704476

DOI: 10.1186/s12918-019-0684-0


Related references

Prospective comparison of early bone marrow evaluation on day 5 versus day 14 of the "3 + 7" induction regimen for acute myeloid leukemia. American Journal of Hematology 90(12): 1159-1164, 2016

New strategies for the evaluation of the nadir bone marrow following induction in acute myeloid leukemia. Current Opinion in Hematology 20(2): 93-99, 2013

Comparison of the therapeutic efficacy of 2 induction regimens for acute myelocytic leukemia by accurate quantitation of bone marrow cellularity. Blut 45(3): 219-220, 1982

Evaluation of bone marrow aspirates in patients with acute myeloid leukemia at day 14 of induction therapy. Diagnostic Pathology 10: 122, 2016

Comparison of the therapeutic efficacity of 2 induction protocols in acute myeloid leukemia using exact quantification of bone marrow cellularity. Onkologie 6(4): 179-183, 1983

A histopathological study of bone marrow in acute myeloid leukemia. Bone marrow biopsy changes before chemotherapy and comparison with bone marrow smears. Zhonghua Nei Ke Za Zhi 30(9): 566-8, 595, 1991

Acute myeloid leukemia in elderly patients Prognostic value of bone marrow aspirate on 14th day of induction treatment. Annals of Hematology 80(Supplement 2): S19, 2001

Cyclophosphamide and total body irradiation versus busulfan and cyclophosphamide A randomized comparison of 2 conditioning regimens in autologous bone marrow transplantation for acute myeloid leukemia. International Journal of Radiation Oncology Biology Physics 30(SUPPL 1): 181-182, 1994

Cyclophosphamide & total body irradiation versus busulfan & cyclophosphamide: A randomized comparison of 2 conditioning regimens in autologous bone marrow transplantation for acute myeloid leukemia. International Journal of Radiation Oncology*biology*physics 30(Supp-S1): 181-182, 1994

Comparison of Peripheral Blast Clearance and Day 14 Bone Marrow Biopsy in Predicting Remission Status and Survival After 7+3 Induction in Acute Myeloid Leukemia. Clinical Lymphoma, Myeloma & Leukemia 2018, 2018

Bone marrow aspirate on the 14th day of induction treatment as a prognostic tool in de novo adult acute myeloid leukemia. Haematologica 85(12): 1285-1290, 2000

Comparison of 2 preparative regimens for bone marrow transplantation in the treatment of children and young adults with acute lympho blastic leukemia. European Journal of Cancer & Clinical Oncology 18(10): 1041, 1982

A randomized Canadian Bone Marrow Transplant Group study comparing peripheral blood and bone marrow allografts in patients undergoing matched sibling transplants for acute myeloid leukemia, chronic myeloid leukemia and myelodysplasia. Blood 94(10 SUPPL 1 PART 1): 163a, Nov 15, 1999

Autologous bone marrow transplantation for patients with acute myeloid leukemia and acute lymphoblastic leukemia a comparison. Bone Marrow Transplantation 1(3): 271-280, 1987

Idarubicin to intensify the conditioning regimens of autologous bone marrow transplantation for patients with acute myeloid leukemia in first complete remission. Bone: 13-19, Y 1, 1998